Business
UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative Cell Therapy for Sensorineural Hearing Loss
Rincell-1 addresses a multi $Bn global market opportunity where no disease modifying treatments currently existSheffield, July 01, 2025 (GLOBE NEWSWIRE) -- UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative Cell Therapy for Sensorineural Hearing Loss Rincell-1 addresses a multi $Bn global market opportunity where no disease modifying treatments currently exist Sheffield, UK, July 1 2025 – Rinri Therapeutics, a world leading company focused on transform
About this update from Brookfield Corporation
[{"type":"text","content":"Rincell-1 addresses a multi $Bn global market opportunity where no disease modifying treatments currently exist","length":111,"tagName":"p"},{"type":"text","content":"Sheffield, July 01, 2025 (GLOBE NEWSWIRE) --","length":44,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":700,"height":441,"url":"https://media.zenfs.com/en/globenewswire.com/b79528f08ea783f7ac48d36189eb748d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/l2R4UVBViYmznR8bCA3Xzg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTYwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b79528f08ea783f7ac48d36189eb748d","width":700,"height":441},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/20AxncXCY8U3URHZbtD6cw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE0MDA7aD04ODI7Y2Y9d2VicA--/https://media.zenfs.com/en/globenewswire.com/b79528f08ea783f7ac48d36189eb748d","width":700,"height":441}}},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"UK MHRA Approval Received for First-In-Human Trial of Rincell-1,","length":64,"tagName":"p"},{"type":"text","content":"a First-In-Class Regenerative Cell Therapy for Sensorineural Hearing Loss","length":73,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"Rincell-1 addresses a multi $Bn global market opportunity ","length":57,"tagName":"p"},{"type":"text","content":"where no disease modifying treatments currently exist","length":53,"tagName":"p"},{"type":"text","content":"Sheffield, UK, July 1 2025 – Rinri Therapeutics, a world leading company focused on transforming sensorineural hearing loss (SNHL) with regenerative cell therapy, is pleased to announce the approval of its Clinical Trial Application (CTA) from the UK MHRA for its lead asset Rincell-1. Clinical proof-of-concept data from the first-in-human Phase I/IIa trial1 of Rincell-1, a first-in-class otic neural progenitor cell therapy, is expected within 12 months of trial initiation.","length":477,"tagName":"p"},{"type":"text","content":"While current standard-of-care treatments like cochlear implants help manage the symptoms of sensorineural hearing loss, their effectiveness depends on the integrity of the cochlear nerve. Rincell-1 has been designed to regenerate damaged auditory neurons, for which no treat...